COMPASS Pathways' (CMPS) Outperform Rating Reaffirmed at Royal Bank of Canada

COMPASS Pathways (NASDAQ:CMPS - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at Royal Bank of Canada in a report released on Wednesday,Benzinga reports. They presently have a $18.00 price objective on the stock. Royal Bank of Canada's price target suggests a potential upside of 427.86% from the company's current price.

CMPS has been the subject of a number of other reports. HC Wainwright lowered their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating for the company in a report on Friday, November 1st. Maxim Group lowered their target price on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, COMPASS Pathways presently has an average rating of "Buy" and a consensus price target of $33.60.

COMPASS Pathways Stock Down 1.2 %

Shares of CMPS stock traded down $0.04 during trading hours on Wednesday, reaching $3.41. The company had a trading volume of 1,466,676 shares, compared to its average volume of 1,571,068. The company has a market capitalization of $233.31 million, a P/E ratio of -1.55 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a twelve month low of $3.16 and a twelve month high of $12.75. The stock's fifty day simple moving average is $4.36 and its 200 day simple moving average is $5.89.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.04. During the same period in the previous year, the firm posted ($0.67) earnings per share. As a group, sell-side analysts expect that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Trading of COMPASS Pathways

Institutional investors have recently added to or reduced their stakes in the stock. Logos Global Management LP grew its holdings in COMPASS Pathways by 349.3% during the 2nd quarter. Logos Global Management LP now owns 1,159,030 shares of the company's stock worth $7,001,000 after acquiring an additional 901,050 shares in the last quarter. Sio Capital Management LLC raised its stake in shares of COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock valued at $5,762,000 after purchasing an additional 621,222 shares in the last quarter. Acuta Capital Partners LLC bought a new position in shares of COMPASS Pathways during the third quarter worth about $2,435,000. Walleye Capital LLC acquired a new position in COMPASS Pathways in the third quarter worth about $2,126,000. Finally, Polar Asset Management Partners Inc. increased its holdings in COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company's stock valued at $3,576,000 after buying an additional 258,000 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.